Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship
News Jul 31, 2013
Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013 and commercial production will immediately begin following regulatory approvals.
"We are pleased to announce this strategic manufacturing relationship with Bristol-Myers Squibb and look forward to delivering best-in-class manufacturing services with the highest global quality standards," said Tae-Han Kim, president and CEO of Samsung BioLogics. “The relationship with Bristol-Myers Squibb represents the validation of our long-term commitment to the biopharmaceutical manufacturing industry.”
"Our agreement with Samsung is an important part of our company’s overall manufacturing and supply strategy focused on creating long-term relationships with high quality manufacturing partners around the world,” said Louis Schmukler, president, Global Manufacturing & Supply, Bristol-Myers Squibb. “This agreement increases our biologic manufacturing capacity to help ensure sufficient long-term supply of our commercial products.”
CMC Biologics Announces Development and Manufacturing Agreement with Harpoon TherapeuticsNews
Companies have entered into agreement for the development and manufacturing of three TriTAC molecules for the treatment of cancers.READ MORE
Serialization Capabilities Now Operational at Lonza Edinburgh Facility for Liquid-Filled Hard CapsulesNews
Investment in former Capsugel site improves anti-counterfeiting security for Lonza’s global supply chain.READ MORE
Changes Identified in Body Cells During Type2 Diabetes OnsetNews
Researchers have found fresh evidence to explain the processes that occur in the body’s cells leading to the onset of type2 diabetes. Utilising metabolomics, results showed that amino acids play a contributory role in the onset of type2 diabetes in some younger and older patients, as the metabolism of specific amino acids is adversely affected.